# A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct06235229/  
OnCo record `nct06235229` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GC012F in multiple myeloma, run by Gracell Biotechnologies (Shanghai) Co., Ltd., now recruiting.

## Summary

A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT06235229 by Gracell Biotechnologies (Shanghai) Co., Ltd., with 110 participants planned, started 2023-12-26 and due to reach its primary completion in 2026-03-02. Interventions recorded: GC012F. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06235229
- Phase: 1/2
- Setting: A Phase I/II Clinical Study of Chimeric Antigen Receptor T-cell Therapy Targeting CD19 and BCMA (GC012F) in Patients With Relapsed/Refractory Multiple Myeloma
- Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd.
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT06235229: https://clinicaltrials.gov/study/NCT06235229

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [GC012F](https://onco.cc/drugs/gc012f/)

---
JSON: https://onco.cc/api/v1/entities/nct06235229.json